Despite an unprecedented rise in the number of biological therapies developed for systemic
lupus erythematosus (SLE) during the last decades, most randomised clinical trials (RCTs) …

Systemic lupus erythematosus (SLE) remains a disease of high unmet clinical need.
Because of substantial patient heterogeneity, the execution of clinical trials that successfully …

Objective: To determine the prevalence of adverse health-related quality of life (HRQoL)
outcomes in patients with SLE who achieved an adequate clinical response after a 52-week …

Introduction Belimumab is a monoclonal antibody against B cell activating factor (BLyS).
This monoclonal antibody (mAb) has been shown to be effective in reducing disease activity …

A noninvasive, easy operation, and accurate diagnostic protocol is highly demanded to
assess systemic lupus erythematosus (SLE) activity during pregnancy, promising real‐time …

Objective The British Isles Lupus Assessment Group–based Composite Lupus Assessment
(BICLA) is a validated global measure of treatment response in systemic lupus …

Objective In trials of systemic lupus erythematosus (SLE), the SLE Responder Index (SRI) is
the most commonly used primary efficacy end point but has limited validation against long …

Methods: The authors synthesized randomized controlled studies (RCTs) from MEDLINE,
Scopus, EMBASE, PubMed, and Cochrane Library until 20 March 2023. The study protocol …

Tobacco companies are investing billions in pharmaceutical and medical products. These
ties complicate the ongoing efforts of researchers, scientific organisations, and journals to …

Although the concept of disease modification is well-established in several immune-
mediated diseases, there is no widely accepted definition of disease modification in …